Compare · KNSA vs RVPH
KNSA vs RVPH
Side-by-side comparison of Kiniksa Pharmaceuticals International plc (KNSA) and Reviva Pharmaceuticals Holdings Inc. (RVPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KNSA and RVPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- KNSA is the larger of the two at $3.77B, about 836.5x RVPH ($4.5M).
- Over the past year, KNSA is up 61.6% and RVPH is down 97.9% - KNSA leads by 159.5 points.
- KNSA has been more active in the news (12 items in the past 4 weeks vs 1 for RVPH).
- Both have 6 recent analyst ratings on file.
- Company
- Kiniksa Pharmaceuticals International plc
- Reviva Pharmaceuticals Holdings Inc.
- Price
- $49.05+1.41%
- $0.36-55.68%
- Market cap
- $3.77B
- $4.5M
- 1M return
- -13.79%
- -59.71%
- 1Y return
- +61.61%
- -97.90%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2020
- News (4w)
- 12
- 1
- Recent ratings
- 6
- 6
Kiniksa Pharmaceuticals International plc
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and psychotic symptoms, dementia or Alzheimer's disease, parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis; and RP1208 that has completed pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.
Latest KNSA
- Director Quart Barry D converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)
- Director Popovits Kimberly J converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)
- CHAIRMAN & CEO Patel Sanj K converted options into 900,000 units of Class A Ordinary Share (SEC Form 4)
- Director Mccain Tracey L converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)
- Director Malley Thomas converted options into 2,799 units of Class A Ordinary Shares, increasing direct ownership by 22% to 15,345 units (SEC Form 4)
- Director Levy Richard S converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 15% to 21,956 units (SEC Form 4)
- Director Cole G Bradley converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)
- Director Baker Bros. Advisors Lp was granted 12,156 units of Class A Ordinary Shares (SEC Form 4)
- Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Latest RVPH
- Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase
- Amendment: SEC Form SCHEDULE 13G/A filed by Reviva Pharmaceuticals Holdings Inc.
- SEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.
- SEC Form 10-Q filed by Reviva Pharmaceuticals Holdings Inc.
- Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- SEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.
- Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine's Potential Across Multiple Neuropsychiatric Indications
- Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits